Sunshine Biopharma, Inc.'s Adva-27a Featured In 2014 Worldwide Uterine Cancer Report For Its Effectiveness Against Multidrug Resistant Uterine Cancer Cells
Published: Jun 10, 2014
MONTREAL, QUEBEC--(Marketwired - June 09, 2014) - Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that Adva-27a, the Company's flagship oncology drug candidate was featured in Global Markets Direct: Uterine Cancer - Pipeline Review, H1 2014 Report for its effectiveness against multidrug resistant uterine cancer cells in vitro.
The Global Markets Direct Uterine Cancer Report provides comprehensive information on the therapeutic development for Uterine Cancer, with comparative analysis, therapeutics assessment, mechanism of action, route of administration and molecule type. The Report also reviews key players involved in the therapeutic development for Uterine Cancer including Sunshine Biopharma Inc.
In December 2012, Sunshine Biopharma announced that it had achieved dramatic effects in Uterine Cancer using its Adva-27a compound. The studies were carried out in MES-SA/Dx5, a Uterine Sarcoma cell line that has become multidrug resistant through the use of a commonly administered chemotherapy drug, Doxorubicin. Adva-27a was able to efficiently kill these cells with an IC50 of less than 8 micromolar, a pharmacologically very favorable drug concentration.
In addition to Uterine Cancer, Adva-27a has been shown to be effective at killing multidrug resistant Breast Cancer cells, Small-Cell Lung Cancer cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).
Sunshine Biopharma recently reported that it has initiated the construction of mouse xenograft models for Pancreatic Cancer as part of the plans of positioning Adva-27a for clinical development for Pancreatic Cancer in parallel with the previously announced multidrug resistant Breast Cancer indication. The first U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.
"We are very pleased that this testing indicated that our drug, Adva-27a, is effective against Uterine Cancer," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "In the U.S. alone, over 52,000 new cases of Uterine Cancer are diagnosed each year. "We are anxious to begin our clinical studies soon and look forward to the opportunity of providing a new treatment for Uterine Cancer patients worldwide," he added.
About The Global Markets Direct: Uterine Cancer - Pipeline Review, H1 2014 Report
The following links provide more information about the Global Markets Direct: Uterine Cancer - Pipeline Review, H1 2014:
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
Help employers find you! Check out all the jobs and post your resume.